Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples